Melior Discovery Enters New Pharmaceutical Collaboration

Melior to Apply Its Unique theraTRACE(SM) Discovery Platform to Identify

Potential New Indications for Multiple Drug Compounds



Aug 06, 2007, 01:00 ET from Melior Discovery, Inc.

    EXTON, Pa., Aug. 6 /PRNewswire/ -- Melior Discovery, Inc. today
 announced that it has signed an agreement with Johnson & Johnson
 Pharmaceutical Research & Development, L.L.C. (J&JPRD) to apply Melior's
 theraTRACE(SM) indications discovery platform to identify possible new
 indications for multiple J&JPRD drug candidates. Financial terms were not
 disclosed.
     Melior's theraTRACE platform is a comprehensive, multiplexed set of
 integrated in vivo models designed to systematically and rapidly identify
 previously unknown applications for pharmaceutical compounds. It can be
 applied to discovery, development stage and marketed agents and has already
 identified novel indications for a number of development stage drugs.
     "This agreement presents a significant opportunity for Melior to
 deliver value through the application of our unique in vivo testing
 platform to a range of pre-clinical and development stage compounds," said
 Andrew Reaume, Ph.D., President and CEO of Melior. "Our theraTRACE
 indications discovery platform is already proving its value in our existing
 collaborations with Merck and Pfizer, as well as in screening for our own
 drug development efforts. We are delighted to be working with J&JPRD, and
 we look forward to a productive collaboration."
     Melior's theraTRACE platform is designed to systematically test the
 potential efficacy of compounds across a large number of disease models
 rapidly and efficiently, using the same high quality in vivo models
 developed by leading pharmaceutical researchers to determine whether a drug
 candidate demonstrates sufficient efficacy to merit advancement into
 clinical development. Melior's proprietary multiplexed approach integrates
 multiple in vivo models and reduces the time, amount of test compound and
 number of test subjects needed, while also reducing the number of false
 positive results. As a result, Melior's platform provides major
 improvements in efficiency and effectiveness and a reduction in the overall
 cost of the new indications discovery effort.
     About Melior Discovery
     Melior Discovery is leading the transformation of pharmaceutical drug
 repositioning with its proprietary theraTRACE platform of multiple
 integrated in vivo models. Melior is using this unique capability to assist
 pharmaceutical and biotechnology partners in realizing the full value of
 their pipeline assets and to build an internal pipeline of development
 candidates. Dr. Christopher Lipinski, a well-known research pioneer who was
 recently named one of the top 10 most influential people in the
 pharmaceutical industry, works closely with Melior in the development of
 its technology and identification of drug candidates.
     For more information, visit http://www.meliordiscovery.com or call Dr.
 Andrew Reaume, President and CEO of Melior.
     Contacts:
     Melior Discovery                        Media:
     Andrew Reaume                           GendeLLindheim BioCom Partners
     President & CEO                         Barbara Lindheim
     (610) 280-0633                          (212) 918-4650
     areaume@meliordiscovery.com
 
 

SOURCE Melior Discovery, Inc.
    EXTON, Pa., Aug. 6 /PRNewswire/ -- Melior Discovery, Inc. today
 announced that it has signed an agreement with Johnson & Johnson
 Pharmaceutical Research & Development, L.L.C. (J&JPRD) to apply Melior's
 theraTRACE(SM) indications discovery platform to identify possible new
 indications for multiple J&JPRD drug candidates. Financial terms were not
 disclosed.
     Melior's theraTRACE platform is a comprehensive, multiplexed set of
 integrated in vivo models designed to systematically and rapidly identify
 previously unknown applications for pharmaceutical compounds. It can be
 applied to discovery, development stage and marketed agents and has already
 identified novel indications for a number of development stage drugs.
     "This agreement presents a significant opportunity for Melior to
 deliver value through the application of our unique in vivo testing
 platform to a range of pre-clinical and development stage compounds," said
 Andrew Reaume, Ph.D., President and CEO of Melior. "Our theraTRACE
 indications discovery platform is already proving its value in our existing
 collaborations with Merck and Pfizer, as well as in screening for our own
 drug development efforts. We are delighted to be working with J&JPRD, and
 we look forward to a productive collaboration."
     Melior's theraTRACE platform is designed to systematically test the
 potential efficacy of compounds across a large number of disease models
 rapidly and efficiently, using the same high quality in vivo models
 developed by leading pharmaceutical researchers to determine whether a drug
 candidate demonstrates sufficient efficacy to merit advancement into
 clinical development. Melior's proprietary multiplexed approach integrates
 multiple in vivo models and reduces the time, amount of test compound and
 number of test subjects needed, while also reducing the number of false
 positive results. As a result, Melior's platform provides major
 improvements in efficiency and effectiveness and a reduction in the overall
 cost of the new indications discovery effort.
     About Melior Discovery
     Melior Discovery is leading the transformation of pharmaceutical drug
 repositioning with its proprietary theraTRACE platform of multiple
 integrated in vivo models. Melior is using this unique capability to assist
 pharmaceutical and biotechnology partners in realizing the full value of
 their pipeline assets and to build an internal pipeline of development
 candidates. Dr. Christopher Lipinski, a well-known research pioneer who was
 recently named one of the top 10 most influential people in the
 pharmaceutical industry, works closely with Melior in the development of
 its technology and identification of drug candidates.
     For more information, visit http://www.meliordiscovery.com or call Dr.
 Andrew Reaume, President and CEO of Melior.
     Contacts:
     Melior Discovery                        Media:
     Andrew Reaume                           GendeLLindheim BioCom Partners
     President & CEO                         Barbara Lindheim
     (610) 280-0633                          (212) 918-4650
     areaume@meliordiscovery.com
 
 SOURCE Melior Discovery, Inc.